This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Clinical Data Interchange Standards Consortium (CDISC) | |
|---|---|
| Name | Clinical Data Interchange Standards Consortium |
| Abbreviation | CDISC |
| Formation | 1997 |
| Type | Nonprofit standards organization |
| Headquarters | United States |
Clinical Data Interchange Standards Consortium (CDISC) The Clinical Data Interchange Standards Consortium (CDISC) is an international standards-developing organization focused on data standards for clinical trials, pharmacovigilance systems, and regulatory submissions. Founded to streamline data interchange among pharmaceutical companies, biotechnology firms, contract research organizations, and regulatory agencys, it produces models and implementation guides that facilitate interoperability among electronic health record systems, laboratory vendors, and statistical analysis platforms. CDISC standards are widely used in submissions to authorities such as the Food and Drug Administration and the European Medicines Agency.
CDISC was formed in 1997 amid growing interest in standardized electronic data interchange in the wake of initiatives by groups like Health Level Seven International and HL7 stakeholders, and parallel efforts such as those by the International Organization for Standardization and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Early contributors included large pharmaceutical companys, academic medical centers, and contract research organizations collaborating with agencies such as the National Institutes of Health and the Food and Drug Administration. During the 2000s, CDISC released foundational models and specifications influenced by projects at institutions like the National Cancer Institute and standards bodies including the Clinical Data Management System community. Milestones included the adoption of models that aligned with the International Council for Harmonisation guidances and engagements with regional regulators such as the Pharmaceuticals and Medical Devices Agency and the Medicines and Healthcare products Regulatory Agency.
CDISC operates as a nonprofit entity governed by a board of directors comprising representatives from pharmaceutical companys, biotechnology firms, academic institutions, and regulatory agencys. Its governance framework includes advisory committees, working groups, and therapeutic area user groups that draw members from contract research organizations, healthcare provider networks, and standards entities like Clinical Data Interchange Standards Consortium peers and allies. CDISC collaborates with international institutions such as the World Health Organization and participates in interoperability forums with organizations like ISO and IEEE. Funding and strategic direction have involved partnerships with trade groups such as the Pharmaceutical Research and Manufacturers of America and consortia including the TransCelerate Biopharma initiative.
CDISC develops a suite of standards including the Study Data Tabulation Model (SDTM), the Analysis Data Model (ADaM), the Clinical Data Acquisition Standards Harmonization (CDASH), and the Operational Data Model (ODM). These models aim to harmonize clinical trial datasets for analysis submissions to regulators such as the Food and Drug Administration and the European Medicines Agency. CDISC standards reference terminologies and controlled vocabularies maintained by organizations like the National Cancer Institute Thesaurus and align with data exchange formats from Health Level Seven International and ISO standards for metadata and data provenance. Specialty implementations include therapeutic area datasets informed by groups such as the Cardiovascular Research Foundation and the Alzheimer's Association.
Clinical operations, biostatistics groups, and data management teams at pharmaceutical companys, academic medical centers, and contract research organizations implement CDISC standards to produce submission-ready datasets for trials overseen by regulators like the Food and Drug Administration and the European Medicines Agency. Electronic data capture vendors, central laboratory providers, and imaging cores integrate CDISC-compliant metadata to facilitate pooled analyses for multi-center trials supported by funders such as the National Institutes of Health and the Bill & Melinda Gates Foundation. Data transformation tools by commercial vendors and open-source projects assist investigators at institutions including Mayo Clinic and Johns Hopkins University to map clinical source data into SDTM and ADaM structures for statistical programming in environments like SAS Institute and R (programming language).
Regulatory authorities including the Food and Drug Administration, the European Medicines Agency, and the Pharmaceuticals and Medical Devices Agency have encouraged or required submission datasets in CDISC formats for certain applications, influencing submission workflows at pharmaceutical companys and biotechnology startups. This regulatory convergence has facilitated multi-jurisdictional submissions in programs overseen by agencies like the Committee for Medicinal Products for Human Use and cooperative review pathways such as the International Council for Harmonisation processes. Adoption has impacted post-marketing surveillance coordinated with organizations like the Uppsala Monitoring Centre and interoperability initiatives promoted by the World Health Organization.
A marketplace of commercial vendors, academic training programs, and professional societies offers CDISC-related software tools, implementation services, and certification curricula used by personnel at contract research organizations, pharmaceutical companys, and academic institutions. Providers include analytics firms, EDC vendors, and consulting organizations that partner with training outlets at universities such as Stanford University and continuing education programs run by industry associations like the Drug Information Association. Certification programs and workshops prepare clinical data managers and biostatisticians for roles in submission preparation for regulators such as the Food and Drug Administration and regional agencies including the European Medicines Agency.
Critiques of CDISC adoption cite complexity, resource demands, and mapping burdens for legacy systems at institutions like community hospitals and small biotechnology firms, echoing concerns raised in interoperability debates involving Health Level Seven International and ISO standards adoption. Challenges include aligning electronic health record exports from vendors with CDISC models, harmonizing controlled vocabularies across terminologies such as the National Cancer Institute Thesaurus and other ontology projects, and ensuring global applicability across regulatory regimes including the Food and Drug Administration and the European Medicines Agency. Ongoing discussions involve balancing prescriptive dataset structures with flexible real-world data integration advocated by consortiums and initiatives such as Observational Health Data Sciences and Informatics and standards efforts at the World Health Organization.
Category:Clinical research